112398-75-1

Basic information

• Product Name: 5-CHLORO-1-METHYLINDOLE
• Synonyms: 5-CHLORO-1-METHYLINDOLE;5-chloro-1-methyl-1H-indole
• CAS NO: 112398-75-1
• Molecular Formula: C₉H₈ClN
• Molecular Weight: 165.62
• Mol File: 112398-75-1.mol
• Article Data: 60

Chemical Properties

• Melting Point: 35 °C(Solv: cyclohexane (110-82-7))
• Boiling Point: 278.4±13.0 °C(Predicted)
• Appearance: /
• Density: 1.18±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 5-CHLORO-1-METHYLINDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-1-METHYLINDOLE(112398-75-1)
• EPA Substance Registry System: 5-CHLORO-1-METHYLINDOLE(112398-75-1)

Safety Data

• Hazardous Substances Data: 112398-75-1(Hazardous Substances Data)

Usage

General Description

5-CHLORO-1-METHYLINDOLE is a chemical compound with the molecular formula C9H8ClN. It is an organic compound that belongs to the indole class of chemicals, which are commonly found in plants and animals. This specific compound is a derivative of indole, with a chlorine atom attached to the fifth carbon and a methyl group attached to the first carbon. It is used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. Its properties and uses make it an important building block in the production of a wide range of chemical products.

Upstream product

• 17422-32-1 5-chloro-1H-indole 
• 74-88-4 methyl iodide 
• 10075-50-0 5-bromo-1H-indole 
• 25658-80-4 5-chloro-2,3-dihydroindole 
• 32617-55-3 5-chloro-1-p-toluenesulfonylindole 
• 865-33-8 potassium methanolate 
• 26663-50-3 5-chloro-1-methylindoline 
• 616-38-6 carbonic acid dimethyl ester 
• 1352622-03-7 1-bromo-2-[(4-chlorophenyl)methylamino]ethanesulfonic acid 2,4,6-trichlorophenyl ester 
• 1352621-91-0 1-bromo-2-(4-chlorophenylamino)ethanesulfonic acid 2,4,6-trichlorophenyl ester 
• 210536-10-0 N-(4-Chloro-2-vinyl-phenyl)-2,2,2-trifluoro-N-methyl-acetamide 
• 932-96-7 N-methyl(p-chloroaniline) 
• 210536-18-8 (4-Chloro-2-vinyl-phenyl)-methyl-amine 
• 181651-29-6 N-(4-chlorophenyl)-N-methylethenesulfinamide 

Downstream Products

• 1018914-02-7 5-chloro-1-methyl-2-phenyl-1H-indole 

Relevant articles and documents

Regioselective 2-alkylation of indoles with α-bromo esters catalyzed by Pd/P,P=O system

A palladium-catalyzed 2-alkylation of indoles with α-bromo esters is developed by employing a P,P=O ligand. The method features excellent regioselectivities, mild reaction conditions, and good functional group compatibility. The employment of the P,P=O ligand as well as 4? molecular sieves were crucial for the success of the transformation. Mechanistic studies indicate the reaction proceed through a radical pathway.

Preparation method of nitrogen-alkyl (deuterated alkyl) aromatic heterocycle and alkyl (deuterated alkyl) aryl ether compound

The invention provides a method for preparing nitrogen-alkyl(deuterated alkyl)aromatic heterocycle and alkyl(deuterated alkyl)aryl ether compounds. The method adopted in the invention specifically comprises the following steps: firstly, adding an alkoxy base (MOR') or a combination reagent Q (comprising a base M'X, an alcohol C and a molecular sieve E) into a solvent B to be stirred; then, addingan aromatic compound D of nitrogen sulfonyl or oxygen sulfonyl into a mixture; separating and purifying after reaction to obtain nitrogen-alkyl(deuterated alkyl)aromatic heterocycle or alkyl(deuterated alkyl)aryl ether. The method can realize one-step conversion from an electron withdrawing benzenesulfonyl protecting group on a nitrogen or oxygen atom to an electron donating alkyl protecting group, avoids using highly toxic alkyl halide, and has advantages of being efficient, economical, environmentally friendly, mild in condition, good in substrate universality and high in yield; the prepareddeuterated compounds can be widely applied to the fields of pharmaceutical chemistry and organic chemistry synthesis.

ARYL HYDROCARBON RECEPTOR ACTIVATORS

Small molecule AhR ligands are disclosed. The ligands can induce the differentiation of Tr1 cells to suppress pathogenic immune responses without inducing nonspecific immune suppression. Methods of treatment of autoimmune diseases using the AhR ligands are also disclosed.